A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
Platinum agents, such as carboplatin and cisplatin, have been recommended in combination with gemcitabine for the treatment of metastatic triple negative breast cancer (TNBC). Here the authors report the results of a randomized phase 3 trial to compare the efficacy of first-line nab-paclitaxel/cispl...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-31704-7 |
| _version_ | 1828746943267864576 |
|---|---|
| author | Biyun Wang Tao Sun Yannan Zhao Shusen Wang Jian Zhang Zhonghua Wang Yue-E Teng Li Cai Min Yan Xiaojia Wang Zefei Jiang Yueyin Pan Jianfeng Luo Zhimin Shao Jiong Wu Xiaomao Guo Xichun Hu |
| author_facet | Biyun Wang Tao Sun Yannan Zhao Shusen Wang Jian Zhang Zhonghua Wang Yue-E Teng Li Cai Min Yan Xiaojia Wang Zefei Jiang Yueyin Pan Jianfeng Luo Zhimin Shao Jiong Wu Xiaomao Guo Xichun Hu |
| author_sort | Biyun Wang |
| collection | DOAJ |
| description | Platinum agents, such as carboplatin and cisplatin, have been recommended in combination with gemcitabine for the treatment of metastatic triple negative breast cancer (TNBC). Here the authors report the results of a randomized phase 3 trial to compare the efficacy of first-line nab-paclitaxel/cisplatin to gemcitabine/cisplatin in patients with TNBC. |
| first_indexed | 2024-04-14T04:33:53Z |
| format | Article |
| id | doaj.art-5b7980c5962a4644aa9b37fc190265f4 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-14T04:33:53Z |
| publishDate | 2022-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-5b7980c5962a4644aa9b37fc190265f42022-12-22T02:11:57ZengNature PortfolioNature Communications2041-17232022-07-011311710.1038/s41467-022-31704-7A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancerBiyun Wang0Tao Sun1Yannan Zhao2Shusen Wang3Jian Zhang4Zhonghua Wang5Yue-E Teng6Li Cai7Min Yan8Xiaojia Wang9Zefei Jiang10Yueyin Pan11Jianfeng Luo12Zhimin Shao13Jiong Wu14Xiaomao Guo15Xichun Hu16Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan UniversityDepartment of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and InstituteDepartment of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan UniversityDepartment of Medical Oncology, Sun Yat-Sen University Cancer Center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer MedicineDepartment of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan UniversityDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan UniversityDepartment of Medical Oncology, The First Hospital of China Medical UniversityDepartment of Medical Oncology, Harbin Medical University Cancer HospitalDepartment of Breast Disease, Henan Breast Cancer Center, The affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalDepartment of Medical Oncology, Zhejiang Cancer HospitalDepartment of Medical Oncology, The Fifth Medical Center of Chinese PLA General HospitalDepartment of Medical Oncology, The First Hospital, Anhui Medical UniversityDepartment of Biostatistics, School of Public Health, Fudan UniversityDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan UniversityDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan UniversityDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan UniversityDepartment of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan UniversityPlatinum agents, such as carboplatin and cisplatin, have been recommended in combination with gemcitabine for the treatment of metastatic triple negative breast cancer (TNBC). Here the authors report the results of a randomized phase 3 trial to compare the efficacy of first-line nab-paclitaxel/cisplatin to gemcitabine/cisplatin in patients with TNBC.https://doi.org/10.1038/s41467-022-31704-7 |
| spellingShingle | Biyun Wang Tao Sun Yannan Zhao Shusen Wang Jian Zhang Zhonghua Wang Yue-E Teng Li Cai Min Yan Xiaojia Wang Zefei Jiang Yueyin Pan Jianfeng Luo Zhimin Shao Jiong Wu Xiaomao Guo Xichun Hu A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer Nature Communications |
| title | A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer |
| title_full | A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer |
| title_fullStr | A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer |
| title_full_unstemmed | A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer |
| title_short | A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer |
| title_sort | randomized phase 3 trial of gemcitabine or nab paclitaxel combined with cisplatin as first line treatment in patients with metastatic triple negative breast cancer |
| url | https://doi.org/10.1038/s41467-022-31704-7 |
| work_keys_str_mv | AT biyunwang arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT taosun arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT yannanzhao arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT shusenwang arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT jianzhang arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT zhonghuawang arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT yueeteng arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT licai arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT minyan arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT xiaojiawang arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT zefeijiang arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT yueyinpan arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT jianfengluo arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT zhiminshao arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT jiongwu arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT xiaomaoguo arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT xichunhu arandomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT biyunwang randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT taosun randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT yannanzhao randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT shusenwang randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT jianzhang randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT zhonghuawang randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT yueeteng randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT licai randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT minyan randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT xiaojiawang randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT zefeijiang randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT yueyinpan randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT jianfengluo randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT zhiminshao randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT jiongwu randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT xiaomaoguo randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer AT xichunhu randomizedphase3trialofgemcitabineornabpaclitaxelcombinedwithcisplatinasfirstlinetreatmentinpatientswithmetastatictriplenegativebreastcancer |